Human Papillomavirus Vaccine
For more information, see Human Papillomavirus (HPV) ACIP Vaccine Recommendations.
Two vaccines are available:
Either vaccine can be used in females; HPV4 is used in males.
Recombinant DNA technology is used to prepare both vaccines from the major capsid (L1) protein of HPV. The L1 proteins self-assemble into noninfectious, nononcogenic virus-like particles (VLPs).
A new vaccine that is effective against 9 types of HPV will soon be available. The new vaccine covers the same types of HPV as the quadrivalent vaccine and adds protection against HPV types 31, 33, 45, 52, and 58, which expands the protection against HPV-related cancers.
The HPV vaccine is a routine childhood vaccination (see Table: Recommended Immunization Schedule for Ages 7–18 yr).
HPV4 or HPV2 is recommended for females at age 11 or 12 yr and for females up through age 26 yr if they were not previously vaccinated.
HPV4 is recommended for males at age 11 or 12 yr and previously unvaccinated males through age 26 yr; HPV4 is recommended for all men who are in this age group and who have sex with men.
Vaccination is recommended for all people who are immunocompromised, including HIV patients, through age 26 if they were not vaccinated at a younger age.
Although HPV vaccines are not recommended for pregnant women, pregnancy testing is not needed before vaccination. If pregnancy is diagnosed after the vaccination series has been started, no intervention is needed, but the remaining doses of the series should be delayed until pregnancy is completed.
The main precaution is